key: cord-0828741-e287tffs
authors: Allaouchiche, Bernard
title: Immunotherapies for COVID-19: restoring the immunity could be the priority
date: 2020-05-20
journal: Anaesth Crit Care Pain Med
DOI: 10.1016/j.accpm.2020.05.009
sha: 5dc6fa0617dddc861a040074dcc60b58840a0708
doc_id: 828741
cord_uid: e287tffs

nan

. Since March 2020 it is a real pandemic affecting most countries in the world.

The treatment of this disease is mostly symptomatic. The optimal treatment is still uncertain. (table 1) . The cytokine storm with its consequences on organs has captured many researchers' attention. Immediately, therapies were proposed to reduce IL-1, IL-6 and TNF-alpha. However, these therapies had failed in the treatment of septic shock and even worsened its prognosis. Anti-interleukin-6 (IL-6) therapies (tocilizumab and sarulimab) have been tried in clinical trials to treat severe COVID-19 patients (2) . However, analysis of plasma levels of interleukin-6 appears to be highly inconsistent. In fact, the concentrations observed are much lower than those observed in septic shock. With regard to the levels of IL-10 (immunosuppressive cytokine), the levels are also high. Moreover, in the majority of cases deep lymphopenia is observed, which is well correlated with mortality. This concerns CD-8 lymphocytes as well as NK cells, which play an important antiviral role. B cells are also affected although they play an important role in the antibody response.

Secondary nosocomial infections are present in more than 50% of cases. Overall, the inflammatory response is modest while immunosuppression appears to be major.

In these conditions, it could be logical to stimulate immunity by using products such as interleukin 7, which appears very interesting to treat other viral infections and allows restoring the lymphocyte count deserved to be used in the treatment of Coronavirus infection.

Stimulating immunity could therefore be a credible alternative to the treatment of Coronavirus 19

infection. What seems essential is to know the immunological state of the patient before using immunomodulating therapies and sometimes use drugs to stimulate immunity. 

An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies

Tocilizumab for the Treatment of Severe COVID-19

The Role of Cytokines including

Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Designing Immunotherapies for the COVID-19 Patient: Lessons Learned from Treating the Septic Patient